B+
Bull case
20%
Probability
Target price
$88.77
Analysis reference price unavailable
Analysis 2026-01-10 · RankAlpha Sentiment AI
CGON
CG OncologyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Successful clinical readouts or a strategic partnership could rapidly re-rate the stock toward premium growth multiples; market attention would likely amplify upside given limited public float and concentrated event risk [#SERP-1].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.8.
What can break
Clinical readout failure or delay
Momentum
28
Value
41
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $63.80 · Bull $88.77 · Bear $38.84Analysis 2026-01-10; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-30 • Vendor: Data Vendor v1
Scores
As of 2026-10-30 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-10-30
Investment thesis
As of 2026-10-30
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-30. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $91.08
Why
Momentum28 · Δ7d -1.6
Value41 · Δ7d +0.0
Sentiment58 · Δ7d +4.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +4.8.
Contradictions & invalidation
- • Clinical readout failure or delay
- • Insufficient cash runway / dilutive financing
- • Negative trial outcomes, missed operational guidance, or a short cash runway would materially compress valuation and push the share price below current levels; small-cap biotech downside tends to be abrupt on binary failures [#SERP-2].
Catalyst clock
2026-03-31
Clinical data readout (assumed window end)
Lead driver: Sentiment · See AI snapshot
Momentum
28
8% active weight
Current posture
7d trendSoftening
Δ7d
-1.6
Δ21d
-20.3
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.2
Sentiment
58
45% active weight
Current posture
7d trendImproving
Δ7d
+4.8
Δ21d
-0.5
Why this grade
Composite grade D. Momentum 28.2 / Value 40.6 / Sentiment 58.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-01-10. Scenario method
Most likely
B
Base case
60%
Probability
Target price
$63.80
Analysis reference price unavailable
Analysis 2026-01-10 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$38.84
Analysis reference price unavailable
Analysis 2026-01-10 · RankAlpha Sentiment AI
Fundamentals (TTM)As of 2026-10-30
Fundamentals (TTM)
As of 2026-10-30
Market Cap
$5.73B
Beta
-
Shares Out
88.64M
P/E (TTM) · Derived
-31.1
P/S (TTM)
1485.68
P/FCF (TTM) · Derived
-29.82
Rev YoY
+1982.7%
EPS YoY
+64.9%
Gross Margin
-93.3%
Op Margin
-4056.2%
Net Debt
-$735.13M
Current Ratio
22.22
As of 2026-10-30 • Updated nightlySource: Internal modelMethods & Data